



[To Authenticate Scan QR Code](#)

Sample Collected At : C000000808-QUALITY CHECK

Bhopal
Madhya Pradesh, INDIA

Name	: DUMMY	Age/Gender	: 25 Years/MALE
Reg No	: 0001EA021782	Barcode No	: E1100001113
Sample Coll Dt	: 31-01-2026 10:09 AM	Reg Date	: 31-01-2026 01:38 PM
Sample Rcv Dt	: 31-01-2026 01:38 PM	Reported Date	: 31-01-2026 02:45 PM
Report Status	: Final	Referred By	: SELF

Tests	Results	Biological Ref Range	Units	Method
-------	---------	----------------------	-------	--------

BIOCHEMISTRY

CA-125, CANCER MARKER, SERUM

CA-125	12.3	0 - 30.2	U/mL	CLIA
Specimen:	SERUM			

Method:CLIA

INTERPRETATION:

Serum CA 125 assay values are useful for monitoring the course of disease in patients with non-invasive epithelial ovarian cancer. Persistently rising CA 125 assay values may be associated with malignant disease and poor response to therapy, whereas decreasing CA 125 assay values may indicate a favorable response to therapy.

INCREASED IN:

a) Malignant disease

Non-mucinous epithelial ovarian carcinoma (85 %), Fallopian tube tumors (100 %), cervical adenocarcinoma (83%), endometrial adenocarcinoma (50%) trophoblastic tumors (45%), cancers of liver, lungs pancreas, squamous cell carcinoma of vulva or cervix (< 15 %). Conditions that affect the endometrial: pregnancy (27%), menstruation endometriosis.

b) Non malignant disease

Cirrhosis, severe liver necrosis (66%), other disease of liver, pancreas, GI tract (5-8%), some disorders of GI tract, renal failure. Healthy persons (1%). Not increased in mucinous carcinoma. Elevated levels of CA 125 are also found in tubercular peritonitis. On treatment levels fall significantly.

INTERFERENCES:

Human antimouse or heterophile antibodies. The CA 125 assay value should be used in conjunction with information available from clinical evaluation and other diagnostic procedures.

** End Of Report**
This report is not subject to use for any medico-legal purposes

Dr. Nitesh Rawat
MD (Pathology)
Consultant Pathologist